499-81-0Relevant articles and documents
Synthesis and crystal structure of metal-organic frameworks [Ln2(pydc-3,5)3(H2O)9]n 3nH2O (Ln = Sm, Eu, Gd, Dy; pydc-3,5 = pyridine-3,5-dicarboxylate) along with the photoluminescent property of its europium one
Shi, Qisong,Zhang, Shu,Wang, Qian,Ma, Hongwei,Yang, Guoqiang,Sun, Wen-Hua
, p. 185 - 189 (2007)
Rare-earth metal-organic frameworks, [Ln2(pydc)3(H2O)9] n3nH2O (Ln = Sm, Eu, Gd, Dy; pydc = pyridine-3,5-dicarboxylate), were synthesized and characterized by elemental analysis, IR spectra and single-crystal X-ray diffraction. The solid-state photoluminescence measurements exhibited red light-emitting characteristic of europium (III) coordination polymer. The title compounds consist of one-dimensional dual chains, in which each metal atom is nine-coordinated with oxygen atoms.
DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS
-
Page/Page column 150, (2016/05/19)
The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
-
, (2008/06/13)
This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.
